Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab as Consolidation Treatment in Limited Stage Small Cell Lung Cancer (ALBORAN)
NCT06992609Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Primary completion
- Jun 2029
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Sep 2025; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06992609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992609.